Oct 2026· Ageing Research Reviews· Vol 123, pp.
103412
· 0 citations· 215 references
Medicine
TL;DR
This review systematically assesses the current evidence linking cellular senescence and SASP to HFpEF and examines the therapeutic potential and limitations of senolytics and senomorphics.
Abstract
Heart failure with preserved ejection fraction (HFpEF) contributes to nearly 50% of the global heart failure (HF) cases, and remains a major clinical challenge because of its heterogeneous pathophysiology, substantial residual morbidity, and limited mechanism-based treatment options. HFpEF is increasingly recognized as a heterogeneous multisystem syndrome closely associated with aging, cardiometabolic comorbidities, and chronic low-grade inflammation. Cellular senescence and the senescence-associated secretory phenotype (SASP) have emerged as potential mechanisms linking several of these systemic stressors to cardiovascular dysfunction. By paracrine and endocrine communication, SASP creates a self-reinforcing circuit in the myocardium. However, the biological consequences of cellular senescence are highly context-, cell type-, and stage-dependent, and transient senescence may exert adaptive or tissue-protective effects under certain conditions. Moreover, much of the current evidence linking senescence to HFpEF remains preclinical or associative, and HFpEF-specific human data are still limited. This review systematically assesses the current evidence linking cellular senescence and SASP to HFpEF and examines the therapeutic potential and limitations of senolytics and senomorphics.
Aging is the predominant risk factor for cardiac dysfunction, driven primarily through a decline in cardiomyocyte and overall myocardial performance. Cellular senescence is becoming increasingly linked to its development, as senescent cardiomyocytes and interstitial cells accumulate with age and exhibit persistent DNA...
Ryan T. Bevington, Amanda L. Johnson, Briana L. Hockey et al.· Aging Cell· 0 citations
Background
Heart failure (HF) with preserved ejection fraction (HFpEF) is associated with aging and systemic inflammation but the role of cellular senescence and its underlying drivers in HFpEF progression remain poorly defined. Activin, a circulating protein that promotes senescence, is increased in many forms of H...
Sheng-Yuan Huang, Chao Wu, Yang Zhang et al.· Circulation· 0 citations
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous, systemic syndrome driven by multiple cardiometabolic stressors. Appropriate preclinical models that recapitulate this complexity are required to dissect cellular mechanisms. The established “two-hit” model (high-fat diet [HFD] + L-NAME) re...
J. Huettemeister, R. Roashanbin, K. Pappritz et al.· European Heart Journal· 0 citations
This review aims to examine the role of clonal hematopoiesis of indeterminate potential (CHIP) in the pathophysiology of heart failure with preserved ejection fraction (HFpEF), focusing on its contribution to inflammation, disease development, and clinical implications. Recent studies demonstrate that CHIP is enriched...
E. Verghote, V. V. van Empel, J. Verdonschot· Current Heart Failure Report...· 0 citations
Heart failure (HF) remains a major cause of morbidity and mortality despite substantial advances in disease-modifying therapy, and clinical improvement does not necessarily indicate complete restoration of myocardial homeostasis. Increasing evidence suggests that inflammatory, stromal, vascular, metabolic, and mitochon...
T. Urbanowicz, M. Kowalewski, Aneta Klotzka et al.· Cells· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.